跳至主要内容
临床试验/NCT06416644
NCT06416644进行中(未招募)不适用

The PORTuguese Registry of Supera Supported Femoral-Fopliteal Revascularization (SupPORT Registry)

Hospital do Divino Espírito Santo de Ponta Delgada29 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2023年4月1日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
100
试验地点
29
主要终点
Target Lesion Revascularization (TLR)

研究概览

简要总结

The SupPORT Registry aims at collecting real-world from Portuguese centers performing femoral-popliteal revascularization with Supera (r) implants. This is a prospective non-randomized non-controlled consecutive registry.

详细描述

Primary endpoints (at hospitalization, 30 days, 6 months, 1 year)

  1. Limb salvage
  2. Target lesion revascularization (TLR)
  3. Freedom from major adverse limb events (MALE - Major Amputation, any index limb revascularization)

Secondary endpoints (at hospitalization, 30 days, 6 months, 1 year)

  1. Freedom from Major adverse cardiovascular events (5-point endpoint: Stroke, myocardial infarction/Acute coronary syndrome, Any limb revascularization, Decompensated Congestive Heart Failure, Cardiovascular death1)
  2. All-cause death / Cardiovascular death
  3. Primary Patency(defined by Duplex Ultrassound Scan [DUS]2) Primary-Assisted Patency, Secondary Patency
  4. Ankle-Brachial Index (ABI)
  5. Rutherford-Becker classification

Inclusion Criteria Clinical

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Evidence of symptomatic obstructive peripheral arterial disease.
  • All-comer patients undergoing endovascular lower-limb revascularization with Supera® stent implantation in the superficial femoral (SFA) or popliteal arteries.
  • Patient or legal representative understand the SupPORT registry procedures, and have voluntarily provided informed written consent regarding their participation.
  • Participant is willing to remain in the SupPORT Registry for at least 1 year.
  • Target lesion is a primary atherosclerotic lesion or a restenosis occurring in a non-stented of the SFA or the popliteal artery, distancing at least ≥ 1 cm from any previously implanted vascular stent.
  • Target lesion causes a ≥50% arterial obstruction (visually confirmed on digital subtraction angiography).

排除标准

  • • Any contraindication for peri-interventional or post-interventional anti-thrombotic therapy (including, but not restricted to Non-fractioned heparina, low-molecular weight heparina [LMWH], Clopidogrel, Ticagrelol, Ticlopidine, Acetylsalicylic acid, dipiridamol, direct thrombin [factor II] or factor Xa inhibitors, vitamin-K antagonists).
  • Participation in other research study that may influence obtained results.
  • Pregnant or breastfeeding women, or expected pregnancy to occur during the study period.
  • Treatment of intrastent restenosis/occlusion of previous peripheral vascular stent.
  • Non-corrected hemodynamically significant obstructive arterial disease of the ipsilateral inflow arteries (aorta, iliac arteries)

结局指标

主要结局

Target Lesion Revascularization (TLR)

时间窗: 1 year

Number of target lesions requiring re-intervention

Freedom from major limb amputation

时间窗: 1 year

Number of limbs surviving without above ankle amputation

MALE - Major Adverse Limb Event

时间窗: 1 year

Composite endpoint Major Amputation, any index limb revascularization

次要结局

  • Primary Patency, Primary Assisted Patency, Secondary Potency(1 year)
  • Ankle-Brachial Index(1 year)
  • Cardiovascular-related death(1 year)
  • All-cause Death(1 year)
  • Rutherford-Becker Classification(1 year)
  • MACE - Major Adverse Cardiovascular Event(1 year)

研究者

发起方
Hospital do Divino Espírito Santo de Ponta Delgada
申办方类型
Other
责任方
Principal Investigator
主要研究者

Dr. Nelson Oliveira

Principal Investigator

Hospital do Divino Espírito Santo de Ponta Delgada

研究点 (29)

Loading locations...

相似试验

The PORTuguese Registry of Supera Supported... | 临床试验